185 related articles for article (PubMed ID: 8950792)
1. The antiplatelet effects of a new nitroderivative of acetylsalicylic acid--an in vitro study of inhibition on the early phase of platelet activation and on TXA2 production.
Lechi C; Andrioli G; Gaino S; Tommasoli R; Zuliani V; Ortolani R; Degan M; Benoni G; Bellavite P; Lechi A; Minuz P
Thromb Haemost; 1996 Nov; 76(5):791-8. PubMed ID: 8950792
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
3. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
[TBL] [Abstract][Full Text] [Related]
4. Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans.
Fiorucci S; Mencarelli A; Meneguzzi A; Lechi A; Renga B; del Soldato P; Morelli A; Minuz P
J Am Coll Cardiol; 2004 Aug; 44(3):635-41. PubMed ID: 15358033
[TBL] [Abstract][Full Text] [Related]
5. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
[TBL] [Abstract][Full Text] [Related]
6. In vitro study of the anti-aggregating activity of two nitroderivatives of acetylsalicylic acid.
Lechi C; Gaino S; Tommasoli R; Zuliani V; Bonapace S; Fontana L; Degan M; Lechi A; Minuz P
Blood Coagul Fibrinolysis; 1996 Mar; 7(2):206-9. PubMed ID: 8735820
[TBL] [Abstract][Full Text] [Related]
7. Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid.
Minuz P; Lechi C; Tommasoli R; Gaino S; Degan M; Zuliani V; Bonapace S; Benoni G; Adami A; Cuzzolin L
Thromb Res; 1995 Dec; 80(5):367-76. PubMed ID: 8588198
[TBL] [Abstract][Full Text] [Related]
8. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
9. Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood.
González-Correa JA; Arrebola MM; Guerrero A; Muñoz-Marín J; Ruiz-Villafranca D; Sánchez de La Cuesta F; De La Cruz JP
Platelets; 2005; 16(3-4):171-9. PubMed ID: 16011961
[TBL] [Abstract][Full Text] [Related]
10. alpha-Naphthoflavone, a potent antiplatelet flavonoid, is mediated through inhibition of phospholipase C activity and stimulation of cyclic GMP formation.
Hsiao G; Chang CY; Shen MY; Chou DS; Tzeng SH; Chen TF; Sheu JR
J Agric Food Chem; 2005 Jun; 53(13):5179-86. PubMed ID: 15969494
[TBL] [Abstract][Full Text] [Related]
11. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
12. Difference of (Ca2+)i movements in platelets stimulated by thrombin and TRAP: the involvement of alpha(IIb)beta3-mediated TXA2 synthesis.
Aoki T; Tomiyama Y; Honda S; Senzaki K; Tanaka A; Okubo M; Takahashi F; Takasugi H; Seki J
Thromb Haemost; 1998 Jun; 79(6):1184-90. PubMed ID: 9657446
[TBL] [Abstract][Full Text] [Related]
13. Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets.
McKenzie ME; Malinin AI; Bell CR; Dzhanashvili A; Horowitz ED; Oshrine BR; Atar D; Serebruany VL
Blood Coagul Fibrinolysis; 2003 Apr; 14(3):249-53. PubMed ID: 12695747
[TBL] [Abstract][Full Text] [Related]
14. Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction.
Liao CH; Cheng JT; Teng CM
Eur J Pharmacol; 2005 Sep; 519(1-2):158-67. PubMed ID: 16112105
[TBL] [Abstract][Full Text] [Related]
15. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
[TBL] [Abstract][Full Text] [Related]
16. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative.
Wallace JL; McKnight W; Del Soldato P; Baydoun AR; Cirino G
J Clin Invest; 1995 Dec; 96(6):2711-8. PubMed ID: 8675638
[TBL] [Abstract][Full Text] [Related]
17. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
[TBL] [Abstract][Full Text] [Related]
18. Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia.
Derhaschnig U; Schweeger-Exeli I; Marsik C; Cardona F; Minuz P; Jilma B
Platelets; 2010; 21(5):320-8. PubMed ID: 20608787
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin.
Chakraborty K; Khan GA; Banerjee P; Ray U; Sinha AK
Platelets; 2003; 14(7-8):421-7. PubMed ID: 14713511
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
Straub A; Wendel HP; Dietz K; Schiebold D; Peter K; Schoenwaelder SM; Ziemer G
Thromb Haemost; 2008 Mar; 99(3):609-15. PubMed ID: 18327411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
